Concord Medical Services (CCM)
NYSE:CCM
Want to see CCM full AI Analyst Report?
Top Page
Concord Medical Services
(NYSE:CCM)
Select Model
Select Model
Rating:46Neutral
Price Target:
$5.00
▲(4.17% Upside)
Action:Reiterated
Date:06/05/26
The score is held down primarily by weak financial performance—ongoing losses, persistent cash burn, and high leverage with negative equity—despite recent improvement. Technicals are modestly supportive with price above key moving averages and a positive MACD, but momentum indicators remain soft. Valuation is also constrained by a negative P/E and no dividend yield data.
Positive Factors
Revenue rebound
A 25.9% revenue rebound in 2025 reflects recovering demand and improved utilization of clinical services. Sustained top-line recovery provides a structural lever to absorb fixed costs, supports scale economics over months, and underpins a path toward margin recovery if maintained.
Negative Factors
High leverage
Substantial debt combined with negative equity creates a structurally weak capital structure that limits financial flexibility. Elevated leverage raises refinancing and covenant risks, increases interest burden, and constrains strategic options unless sustained profitability or capital relief arrives.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
A 25.9% revenue rebound in 2025 reflects recovering demand and improved utilization of clinical services. Sustained top-line recovery provides a structural lever to absorb fixed costs, supports scale economics over months, and underpins a path toward margin recovery if maintained.
Read all positive factors
Concord Medical Services (CCM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$21.97M
Dividend YieldN/A
Average Volume (3M)25.64K
Price to Earnings (P/E)―
Beta (1Y)0.36
Revenue Growth20.26%
EPS Growth69.68%
CountryUS
Employees595
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,815,458
10 Day Avg. Volume72,657
30 Day Avg. Volume25,639
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00853
P/FCF Ratio-0.01
Enterprise Value/Market Cap152.12
Enterprise Value/Revenue9.14
Enterprise Value/Gross Profit-79.86
Enterprise Value/Ebitda-9.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Concord Medical Services Business Overview & Revenue Model
Company Description
Concord Medical Services Holdings Limited, together its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in two segments, Network and Hospital. Its services inc...
How the Company Makes Money
CCM makes money primarily by providing healthcare services through its owned and/or managed medical facilities and by charging for clinical services delivered to patients (for example, diagnostics and treatment services historically associated wit...
Concord Medical Services Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 365.76M | 460.51M | 383.96M | 537.40M | 472.08M | 485.63M |
| Gross Profit | -41.85M | 25.82M | -79.16M | -76.61M | -152.41M | -56.90M |
| EBITDA | -358.51M | -71.77M | -345.62M | -344.16M | -401.86M | -363.86M |
| Net Income | -163.12M | -92.81M | -308.24M | -297.66M | -489.66M | -271.43M |
Balance Sheet | ||||||
| Total Assets | 6.73B | 6.55B | 6.73B | 6.05B | 6.00B | 6.23B |
| Cash, Cash Equivalents and Short-Term Investments | 177.39M | 297.79M | 350.85M | 58.14M | 158.28M | 157.39M |
| Total Debt | 3.82B | 3.63B | 3.93B | 3.30B | 3.24B | 2.73B |
| Total Liabilities | 5.01B | 4.70B | 5.11B | 4.31B | 3.99B | 3.49B |
| Stockholders Equity | -2.24B | -2.10B | -2.28B | -2.12B | -1.86B | -1.37B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -293.16M | -808.58M | -392.17M | -600.47M | -1.12B |
| Operating Cash Flow | 0.00 | -201.82M | -397.75M | -276.47M | -216.69M | -359.31M |
| Investing Cash Flow | 0.00 | 53.97M | -593.44M | -47.68M | -118.79M | -565.98M |
| Financing Cash Flow | 0.00 | 197.23M | 1.15B | 257.65M | 383.09M | 642.45M |
Concord Medical Services Technical Analysis
Positive
4.80
Price Trends
4.40
Positive
4.16
Positive
4.60
Positive
Market Momentum
0.11
Positive
56.80
Neutral
31.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCM, the sentiment is Positive. The current price of 4.8 is below the 20-day moving average (MA) of 5.04, above the 50-day MA of 4.40, and above the 200-day MA of 4.60, indicating a bullish trend. The MACD of 0.11 indicates Positive momentum. The RSI at 56.80 is Neutral, neither overbought nor oversold. The STOCH value of 31.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCM.
Concord Medical Services Risk Analysis
Concord Medical Services disclosed 78 risk factors in its most recent earnings report. Concord Medical Services reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
We may have conflicts of interest with our subsidiary Concord Healthcare which is a stand-alone public company. Q4, 2023
2.
Concord Healthcare may need to raise more capital, which could dilute our equity stake or impose debt service obligations on Concord Healthcare, if such capital is available at all. Q4, 2023
Concord Medical Services Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $117.32M | 36.30 | 16.94% | ― | -35.82% | ― | |
55 Neutral | $79.84M | -0.30 | 184.97% | ― | -0.87% | 10.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $9.14M | -5.81 | -8.75% | ― | -0.62% | -200.79% | |
46 Neutral | $21.97M | -0.03 | ― | ― | 20.26% | 69.68% | |
46 Neutral | $28.19M | -10.58 | 15.82% | 11.14% | -2.56% | -2181.76% | |
44 Neutral | $56.31M | -0.29 | -88.97% | ― | -42.03% | -28904.55% |
* Healthcare Sector Average
CCM
Concord Medical Services
4.78
-2.32
-32.68%
AMS
American Shared Hospital Services
1.33
-1.26
-48.65%
JYNT
Joint
8.29
-3.63
-30.45%
CCEL
Cryo-Cell International
3.49
-1.61
-31.57%
DCGO
DocGo
0.56
-1.04
-65.06%
PIII
P3 Health Partners
11.58
5.02
76.52%
Concord Medical Services Corporate Events
Concord Medical Reviews Consolidation Status After Board Changes at Concord Healthcare
May 18, 2026
Concord Medical Services reported governance changes at its Hong Kong-listed affiliate Concord Healthcare Group Co., Ltd., noting that executive director Liang Chang resigned on May 11, 2026, for personal career planning reasons, while employee re...
Concord Medical’s Hong Kong Subsidiary Raises HK$68 Million via 2027 Convertible Bonds
May 13, 2026
Concord Medical Services’ subsidiary Concord Healthcare Group completed the issuance of 2% convertible bonds due 2027 with an aggregate principal amount of HK$68 million on May 13, 2026, under a placing and subscription agreement signed on M...
Concord Medical’s Hong Kong Subsidiary Reshapes Board Leadership After AGM
May 13, 2026
At the May 11, 2026 annual general meeting of Concord Healthcare Group Co., Ltd., a subsidiary of Concord Medical Services Holdings Limited, president Wei Jiang was appointed as an executive director, replacing retiring executive director Xiao Fu....
Concord Medical Subsidiary Concord Healthcare Files 2025 Annual Report in Hong Kong
Apr 15, 2026
Concord Healthcare Group Co., Ltd., a subsidiary of Concord Medical Services Holdings Limited, filed its annual report for the year ended December 31, 2025 on the Main Board of the Hong Kong Stock Exchange on April 15, 2026. The filing marks a fur...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.